Top Trending KOLs
October 2025
| # | KOL | Engagement Score | Influence Overview |
|---|---|---|---|
| 1 |
Dr. Stephen V. Liu Lombardi Comprehensive Cancer Center |
1 |
Dr. Liu was the top influencer at #ESMO25 in the lung cancer space. He was actively involved in discussing results from trials HARMONi-6 and OptiTROP-Lung04.
View post
|
| 2 |
Dr. Jarushka Naidoo Beaumont RCSI Cancer Centre |
2 |
During #ESMO25, Dr. Naidoo provided insights on the MDT-BRIDGE trial and shares what she calls disruptive science from the #LungMATE-013 trial on lung cancer mini orals.
View post
|
| 3 |
Dr. Eric Singhi MD Anderson Cancer Center |
3 |
During #ESMO25, Dr. Singhi shares thoughts regarding the #NORTHSTAR clinical trial, as well as the #MDTBRIDGE clinical trial. He's also involved in discussions regarding options for patients with HER2+ mNSCLC. Dr. Singhi champions inclusion and diversity in trial enrollment. |
| 4 |
Dr. Balazs Halmos Montefiore Health System |
4 |
Dr. Halmos shares data and discussion around clinical trials, OptiTROP-Lunf04, HARMONi and DeLLphi-303.
|
| 5 |
Dr. Julia Rotow Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institutue |
5 |
During #ASCO25, Dr. Rotow along with the DFCI EGFR Center shared updates on emerging data from the following clinical trials: OptiTROP-Lung03 |
| 6 |
Dr. Suresh Ramalingam Winship Cancer Institute of Emory University |
6 |
At #WCLC25 Dr. Ramalingam was the discussant for the HARMONi data and noted the significant progression-free survival benefit with ivonescimab but highlighted that the statistically significant benefit was less pronounced in Western patients compared to Asian patients. He also expressed caution regarding the overall survival data, which did not meet statistical significance, and downplayed the additional nominal p-value reported by Summit Therapeutics. |
| # | KOL | Engagement Score | Influence Overview |
|---|---|---|---|
| 1 |
Dr. Erika Hamilton Sarah Cannon Research Institute |
1 |
Dr. Hamilton was the top influencer at #ESMO25 in the breast cancer space. She provided insights on TROP-2 ADC presentations and detailed analysis on several breast cancer-related studies.
View post
|
| 2 |
Dr. Sarah Sammons Dana-Farber Cancer Institute |
2 |
During #ESMO25, Dr. Sammons discussed ADCs in HER2+ breast cancer patients.
View post
|
| 3 |
Dr. Paolo Tarantino Dana-Farber Cancer Institute |
3 |
Dr. Tarantino provided important commentary and reminders based on data from a key breast cancer clinical trial, DESTINY-Breast11.
View post
|
| 4 |
Dr. Stephanie Graff Brown University Health |
4 |
During #ESMO25 she engaged in discussions on breast cancer treatment strategies and ongoing debates in the breast cancer space. She highlighted findings from the SONIA, BEGONIA and ASCENT-o4 clinical trials.
View post
|
| 5 |
Dr. Hope Rugo City of Hope |
5 |
Dr. Rugo engaged in discussions on adjuvant therapies, providing commentary and analysis of trials, of particular importance is the 5 year updated on the NATALEE trial.
View post
|
| 6 |
Dr. Harold Burstein Dana-Farber Cancer Institute |
6 |
Dr. Burstein offered perspectives on adjuvant CDK46 inhibitors, contributing to the ongoing dialogue on treatment directions.
View post
|
| 7 |
Dr. Sara Tolaney Dana-Farber Cancer Institute |
7 |
During #ASCO25, Dr. Tolaney commented that the results from the ASCENT-04/KEYNOTE-D19 Trial, support the combination of #sacituzumab plus #pembrolizumab as a potential new standard of care for patients with previously untreated, PD-L1-positive metastatic #TripleNegativeBreastCancer. |
| 8 |
Dr. Antonio Giordano Dana-Farber Cancer Institute |
8 |
During ESMO #25 Dr. Giordano provided insights into advances in breast cancer, particularly related to long-term outcomes and treatment strategies.
View post
|
| # | KOL | Engagement Score | Influence Overview |
|---|---|---|---|
| 1 |
Dr. Rahul Banerjee Fred Hutch Cancer Center |
1 |
Dr. Banerjee was the top influencer at #IMS25 sharing content from his peers in real-time and engaging in discussions with many of his other myeloma expert colleagues.
View post
|
| 2 |
Dr. Saad Usmani MD Anderson Cancer Center |
2 |
Dr. Usmani's presentation at IMS25 on the ability to cure multiple myeloma in the next 10 years was a trending discussion among the Myeloma KOL community.
View post
|
| 3 |
Dr. Samer Al Hadidi UTSW Simmons Cancer Center |
3 |
Popular Tweet is a grand rounds presentation on Current Perspectives in the Management of Smoldering Multiple Myeloma
View post
|
| # | KOL | Engagement Score | Influence Overview |
|---|---|---|---|
| 1 |
Dr. Cathy Eng Vanderbilt Health |
1 |
Dr. Eng discusses the STELLAR-303 clinical trial, noting the modest increase in OS. She also shares data on ABC-HCC, ZASB-neoGOLP study, CheckMate 8HW and BREAKWATER.
View post
|
| # | KOL | Engagement Score | Influence Overview |
|---|---|---|---|
| 1 |
Dr. Elizabeth Plimack Fox Chase Cancer Center |
1 |
A top KOL influencer, Dr. Plimack, shared insights on the KEYNOTE-905/EV-303 a phase 3 study evaluating the efficacy and safety of perioperative pembrolizumab or pembrolizumab + enfortumab vedotin for MIBC.
View post
Her Trial Review: perioperative enfortumab vedotin + pembrolizumab significantly improved EFS, OS, and pCR in cisplatin-ineligible MIBC. |
